[1]
|
Chiang, C.E., Chao, T.F., Choi, E.K., et al. (2022) Stroke Prevention in Atrial Fibrillation: A Scientific Statement of JACC: Asia (Part 1). JACC Asia, 2, 395-411. https://doi.org/10.1016/j.jacasi.2022.05.005
|
[2]
|
Kühne, M., Krisai, P., Coslovsky, M., et al. (2022) Silent Brain Infarcts Impact on Cognitive Function in Atrial Fibrillation. European Heart Journal, 43, 2127-2135. https://doi.org/10.1093/eurheartj/ehac020
|
[3]
|
Burdett, P. and Lip, G.Y.H. (2022) Atrial Fibrillation in the UK: Predicting Costs of an Emerging Epidemic Recognizing and Forecasting the Cost Drivers of Atrial Fibrillation-Related Costs. European Heart Journal—Quality of Care and Clinical Outcomes, 8, 187-194. https://doi.org/10.1093/ehjqcco/qcaa093
|
[4]
|
January, C.T., Wann, L.S., Calkins, H., et al. (2019) 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/ HRS Guideline for the Management of Patients with Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Prac-tice Guidelines and the Heart Rhythm Society in Collaboration with the Society of Thoracic Surgeons. Circulation, 140, e125-e151.
https://doi.org/10.1161/CIR.0000000000000665
|
[5]
|
Choi, S.E., Sagris, D., Hill, A., et al. (2023) Atrial Fibrilla-tion and Stroke. Expert Review of Cardiovascular Therapy, 21, 35-56. https://doi.org/10.1080/14779072.2023.2160319
|
[6]
|
Catalani, F., Campello, E., Occhipinti, G., et al. (2023) Effi-cacy and Safety of direct Oral Anticoagulants in Older Adults with Atrial Fibrillation: A Prospective Single-Centre Co-hort Study. Internal and Emergency Medicine, 18, 1941-1949. https://doi.org/10.1007/s11739-023-03375-9
|
[7]
|
Piero Perna, G., Vora, P., Gandini, E., et al. (2023) Persistence to Rivaroxaban Therapy for Stroke Prevention in Clinical Practice in Italy: Rationale and Design of the RITMUS-AF Prospective Observational Cohort Study. International Journal of Cardiology: Heart & Vasculature, 47, Article ID: 101229. https://doi.org/10.1016/j.ijcha.2023.101229
|
[8]
|
Cools, F., Johnson, D., Camm, A.J., et al. (2021) Risks Associated with Discontinuation of Oral Anticoagulation in Newly Diagnosed Patients with Atrial Fibrillation: Results from the GARFIELD-AF Registry. Journal of Thrombosis and Haemostasis, 19, 2322-2334. https://doi.org/10.1111/jth.15415
|
[9]
|
Barnes, G.D., Ageno, W., Castellucci, L.A., et al. (2023) Recommendation on the Nomenclature for Anticoagulants: Updated Communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Committee on the Control of Anticoagulation. Journal of Thrombosis and Haemostasis, 21, 1381-1384.
https://doi.org/10.1016/j.jtha.2023.02.008
|
[10]
|
Chaudhry, R., Usama, S.M. and Babiker, H.M. (2023) Physiology, Coagulation Pathways. StatPearls Publishing, Treasure Island.
|
[11]
|
Bortman, L.V., Mitchell, F., Naveiro, S., et al. (2023) Direct Oral Anticoagulants: An Updated Systematic Review of Their Clinical Pharmacology and Clinical Effectiveness and Safety in Patients with Nonvalvular Atrial Fibrillation. The Journal of Clinical Pharmacology, 63, 383-396. https://doi.org/10.1002/jcph.2184
|
[12]
|
Bhatia, K., Ladd, L.M., Carr, K.H., et al. (2023) Contemporary Antiplatelet and Anticoagulant Therapies for Secondary Stroke Prevention: A Narrative Review of Current Literature and Guidelines. Current Neurology and Neuroscience Reports, 23, 235-262. https://doi.org/10.1007/s11910-023-01266-2
|
[13]
|
中华医学会心电生理和起搏分会, 中国医师协会心律学专业委员会, 中国房颤中心联盟心房颤动防治专家工作委员会. 心房颤动: 目前的认识和治疗建议(2021) [J]. 中华心律失常学杂志, 2022, 26(1): 15-88.
|
[14]
|
Hindricks, G., Potpara, T., Dagres, N., et al. (2021) 2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation De-veloped in Collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the Diagnosis and Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Developed with the Spe-cial Contribution of the European Heart Rhythm Association (EHRA) of the ESC. European Heart Journal, 42, 373-498. https://doi.org/10.1093/eurheartj/ehaa798
|
[15]
|
Wang, M., Zeraatkar, D., Obeda, M., et al. (2021) Drug-Drug Inter-actions with Warfarin: A Systematic Review and Meta-Analysis. British Journal of Clinical Pharmacology, 87, 4051-4100. https://doi.org/10.1111/bcp.14833
|
[16]
|
Dawwas, G.K., Cuker, A., Barnes, G.D., et al. (2022) Apixa-ban versus Rivaroxaban in Patients with Atrial Fibrillation and Valvular Heart Disease: A Population-Based Study. An-nals of Internal Medicine, 175, 1506-1514.
https://doi.org/10.7326/M22-0318
|
[17]
|
García-Sempere, A., Hurtado, I., Bejarano-Quisoboni, D., et al. (2019) Quality of INR Control and Switching to Non-Vitamin K Oral Anticoagulants between Women and Men with Atrial Fi-brillation Treated with Vitamin K Antagonists in Spain. A Population-Based, Real-World Study. PLOS ONE, 14, e0211681.
https://doi.org/10.1371/journal.pone.0211681
|
[18]
|
Mansour, H., Lubbad, R., Aboobaid, H., et al. (2022) Compli-ance amongst Recipients of Warfarin to Treat Non-Valvular Atrial Fibrillation: A Cross-Sectional Study. The Lancet, 399, S5. https://doi.org/10.1016/S0140-6736(22)01140-0
|
[19]
|
Sun, B., Ma, S., Xiao, F., et al. (2023) Integrated Analy-sis of Clinical and Genetic Factors on the Interindividual Variation of Warfarin Anticoagulation Efficacy in Clinical Prac-tice. BMC Cardiovascular Disorders, 23, Article No. 279.
https://doi.org/10.1186/s12872-023-03321-9
|
[20]
|
Chan, Y.H., Lee, H.F., See, L.C., et al. (2019) Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients with Nonvalvular Atrial Fibrillation. Chest, 156, 529-543. https://doi.org/10.1016/j.chest.2019.04.108
|
[21]
|
Archontakis-Barakakis, P., Li, W., Kalaitzoglou, D., et al. (2022) Effectiveness and Safety of Intracranial Events Associated with the Use of Direct Oral Anticoagulants for Atrial Fibrilla-tion: A Systematic Review and Meta-Analysis of 92 Studies. British Journal of Clinical Pharmacology, 88, 4663-4675. https://doi.org/10.1111/bcp.15464
|
[22]
|
Durand, M., Schnitzer, M.E., Pang, M., et al. (2020) Comparative Effec-tiveness and Safety of Direct Oral Anticoagulants versus Vitamin K Antagonists in Nonvalvular Atrial Fibrillation: A Canadian Multicentre Observational Cohort Study. CMAJ Open, 8, E877-E886. https://doi.org/10.9778/cmajo.20200055
|
[23]
|
Davis, M.K., Lim, H. and Lee, A.Y.Y. (2021) Direct Oral Anticoag-ulants in Patients with Cancer and Nonvalvular Atrial Fibrillation. JACC: CardioOncology, 3, 425-427. https://doi.org/10.1016/j.jaccao.2021.07.003
|
[24]
|
Zhou, H., Nie, X., Jiang, M., et al. (2022) Cost-Effectiveness of Anticoagulants for Preventing Stroke in Patients with Non-Valvular Atrial Fibrillation in Mainland China. Journal of Clinical Pharmacy and Therapeutics, 47, 523-530.
https://doi.org/10.1111/jcpt.13575
|
[25]
|
Enomoto, A., Mano, Y., Kawano, Y., et al. (2021) Comparison of the Safety and Effectiveness of Four Direct Oral Anticoagulants in Japanese Patients with Nonvalvular Atrial Fibrillation Using Real-World Data. Biological and Pharmaceutical Bulletin, 44, 1294-1302. https://doi.org/10.1248/bpb.b21-00230
|
[26]
|
Durand, M., Schnitzer, M.E., Pang, M., et al. (2021) Effectiveness and Safety among Direct Oral Anticoagulants in Nonvalvular Atrial Fibrillation: A Multi-Database Cohort Study with Me-ta-Analysis. British Journal of Clinical Pharmacology, 87, 2589-2601. https://doi.org/10.1111/bcp.14669
|
[27]
|
Nemola, G., Russi, A., Cozzani, G., et al. (2023) Baseline Characteristics and 3-Year Outcome of Nonvalvular Atrial Fibrillation Patients Treated with the Four Direct Oral Anticoagulants (DO-ACs). American Journal of Cardiology, 206, 125-131. https://doi.org/10.1016/j.amjcard.2023.07.181
|
[28]
|
Jansson, M., Själander, S., Sjögren, V., et al. (2020) Direct Comparisons of Effectiveness and Safety of Treatment with Apixaban, Dabigatran and Rivaroxaban in Atrial Fibrillation. Thrombosis Research, 185, 135-141.
https://doi.org/10.1016/j.thromres.2019.11.010
|
[29]
|
Volgman, A.S., Nair, G., Lyubarova, R., et al. (2022) Man-agement of Atrial Fibrillation in Patients 75 Years and Older: JACC State-of-the-Art Review. Journal of the American College of Cardiology, 79, 166-179.
https://doi.org/10.1016/j.jacc.2021.10.037
|
[30]
|
Rubino, C., Blunda, F., Bodega, F., et al. (2023) Safety and Effica-cy of Direct Oral Anticoagulants (DOACs) in Very Elderly Patients (≥85 Years Old) with Non-Valvular Atrial Fibrilla-tion. Minerva Medica, 114, 137-147.
https://doi.org/10.23736/S0026-4806.21.07432-2
|
[31]
|
Naganuma, M., Shiga, T. and Hagiwara, N. (2020) Clinical Outcomes of Direct Oral Anticoagulants and Warfarin in Japanese Patients with Atrial Fibrillation Aged ≥ 85 Years: A Single-Center Observational Study. Drugs: Real World Outcomes, 7, 325-335. https://doi.org/10.1007/s40801-020-00209-4
|
[32]
|
Shiozawa, M., Koga, M., Inoue, H., et al. (2023) Risk of both Intracranial Hemorrhage and Ischemic Stroke in Elderly Individuals with Nonvalvular Atrial Fibrillation Taking Direct Oral Anticoagulants Compared with Warfarin: Analysis of the ANAFIE Registry. International Journal of Stroke, 18, 986-995. https://doi.org/10.1177/17474930231175807
|
[33]
|
Lo, C.T., Niu, F., Fredriks, D.A., et al. (2022) Evalua-tion of the Effectiveness and Safety of Direct Oral Anticoagulants in Elderly Patients with Nonvalvular Atrial Fibrillation Who Are Not Candidates for Warfarin in Real-World Setting. Journal of Cardiovascular Pharmacology, 79, e138-e143. https://doi.org/10.1097/FJC.0000000000001168
|
[34]
|
Ferrari, F., da Silveira, A.D., Martins, V.M., et al. (2021) Direct-Acting Oral Anticoagulants in Atrial Fibrillation: What’s New in the Literature. Cardiology in Review, 29, 120-130. https://doi.org/10.1097/CRD.0000000000000312
|
[35]
|
Harrington, J., Carnicelli, A.P., Hua, K., et al. (2023) Direct Oral Anticoagulants versus Warfarin across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses from COMBINE AF. Circulation, 147, 1748-1757.
https://doi.org/10.1161/CIRCULATIONAHA.122.062752
|
[36]
|
Mapili, J.A.L., Lim, L.C.S., Velando, B.M., et al. (2023) The Safety and Efficacy of Direct Oral Anticoagulants among Chronic Kidney Disease Patients on Dialysis with Non-Valvular Atrial Fibrillation: A Meta-Analysis. Frontiers in Cardiovascular Medicine, 10, Article ID: 1261183. https://doi.org/10.3389/fcvm.2023.1261183
|
[37]
|
Gorbatenko, V.S., Gerasimenko, A.S. and Shatalova, O.V. (2020) Comparative Efficacy and Safety of Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Chronic Kidney Disease. Kardiologiia, 60, 102-109.
https://doi.org/10.18087/cardio.2020.9.n1178
|
[38]
|
Costache, R.S., Dragomirică, A.S., Gheorghe, B.E., et al. (2023) Oral Anticoagulation in Patients with Chronic Liver Disease. Medicina (Kaunas), 59, Article No. 346. https://doi.org/10.3390/medicina59020346
|
[39]
|
中华医学会心血管病学分会, 中国生物医学工程学会心律分会. 心房颤动诊断和治疗中国指南[J]. 中华心血管病杂志, 2023, 51(6): 572-618.
|
[40]
|
Lee, H.F., Chan, Y.H., Chang, S.H., et al. (2019) Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients with Nonvalvular Atrial Fibrillation. Journal of the American Heart Association, 8, e011112. https://doi.org/10.1161/JAHA.118.011112
|
[41]
|
Douros, A., Cui, Y., Platt, R.W., et al. (2022) Utilization and Long-Term Persistence of Direct Oral Anticoagulants among Patients with Nonvalvular Atrial Fibrillation and Liver Dis-ease. British Journal of Clinical Pharmacology, 88, 994-1009. https://doi.org/10.1111/bcp.15046
|
[42]
|
Cao, D., Amabile, N., Chiarito, M., et al. (2023) Reversal and Removal of Oral Antithrombotic Drugs in Patients with Active or Perceived Imminent Bleeding. European Heart Journal, 44, 1780-1794.
https://doi.org/10.1093/eurheartj/ehad119
|
[43]
|
van Es, N., De Caterina, R. and Weitz, J.I. (2023) Reversal Agents for Current and Forthcoming Direct Oral Anticoagulants. European Heart Journal, 44, 1795-1806. https://doi.org/10.1093/eurheartj/ehad123
|
[44]
|
Gómez-Outes, A., Alcubilla, P., Calvo-Rojas, G., et al. (2021) Me-ta-Analysis of Reversal Agents for Severe Bleeding Associated with Direct Oral Anticoagulants. Journal of the American College of Cardiology, 77, 2987-3001.
https://doi.org/10.1016/j.jacc.2021.04.061
|
[45]
|
Steffel, J., Collins, R., Antz, M., et al. (2021) 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace, 23, 1612-1676.
https://doi.org/10.1093/europace/euab157
|
[46]
|
Reed, M., Tadi, P. and Nicolas, D. (2023) Andexanet Alfa. StatPearls Publishing, Treasure Island.
https://doi.org/10.1055/s-0041-1740180
|
[47]
|
Benz, A.P., Xu, L., Eikelboom, J.W., et al. (2022) Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban. Thrombosis and Haemostasis, 122, 998-1005.
https://doi.org/10.1016/j.jacc.2020.04.053
|
[48]
|
Tomaselli, G.F., Mahaffey, K.W., Cuker, A., et al. (2020) 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology, 76, 594-622.
https://doi.org/10.1016/j.cpcardiol.2022.101483
|
[49]
|
Biswas, S., Bahar, Y., Bahar, A.R., et al. (2023) Present Knowledge on Direct Oral Anticoagulant and Novel Oral Anti Coagulants and Their Specific Antidotes: A Comprehen-sive Review Article. Current Problems in Cardiology, 48, Article ID: 101483. https://doi.org/10.1182/blood.2020007116
|
[50]
|
Ansell, J., Laulicht, B.E., Bakhru, S.H., et al. (2021) Ciraparantag, an Anticoagulant Reversal Drug: Mechanism of Action, Pharmacokinetics, and Reversal of Anticoagulants. Blood, 137, 115-125.
|
[51]
|
Piccini, J.P., Caso, V., Connolly, S.J., et al. (2022) Safety of the Oral Factor XIa Inhibitor Asundexian Compared with Apixaban in Patients with Atrial Fibrillation (PACIFIC-AF): A Multicentre, Randomised, Double-Blind, Double-Dummy, Dose-Finding Phase 2 Study. The Lancet, 399, 1383-1390.
|
[52]
|
De Caterina, R., Prisco, D. and Eikelboom, J.W. (2023) Factor XI Inhibitors: Cardiovascular Perspectives. European Heart Journal, 44, 280-292. https://doi.org/10.1093/eurheartj/ehac464
|
[53]
|
Greco, A., Laudani, C., Spagnolo, M., et al. (2023) Pharmacology and Clinical Development of Factor XI Inhibitors. Circulation, 147, 897-913. https://doi.org/10.1161/CIRCULATIONAHA.122.062353
|